Arizona Bioscience Overview
Arizona is home to one of the fastest growing bioscience industries in the U.S. Watch the video to see how a statewide collaboration built the research infrastructure and attracted a growing talent base of thought leaders committed to making Arizona a leading bioscience state.
Company Presentation: NuvOx
NuvOx Pharma is a biotechnology company based in Tucson, Arizona with a novel patent portfolio allowing it to develop an innovative platform of dodecafluoropentane (DDFP)-based oxygen therapeutics to treat a host of human conditions. Founded in 2008, NuvOx Pharma has demonstrated therapeutic feasibility in radiation-resistant cancer, hemorrhagic shock, traumatic brain injury, myocardial infarction, retinopathy and stroke. Due to inherent structure of DDFP, a very stable and relative lack of inter-molecular attractive forces, this perfluorocarbon is known to carry large payloads of oxygen in the bloodstream. The main advantage to using DDFP is that it is a liquid at room temperature, but expands to the gas state in the body. Therefore, upon intravenous injection the transition of DDFP from a liquid to a gas in the bloodstream allows for ~600 times increased oxygen transport compared to Hemoglobin.
Senestech: Humane Pest Control
Senestech is a platform biotechnology company specializing in reproductive physiology. Our mission: Senestech aims to provide for the more humane treatment of animals, to improve the quality of human life, and to enhance environmental stewardship through global application of our animal fertility control technology. We are currently applying our revolutionary technology to the control of rats and mice in both agricultural and urban settings.
2012 State of the Industry: John D. Carroll of FierceBiotech
John D. Carroll is a biotech analyst with 34 years of prize-winning experience in journalism. Appointed editor of FierceBiotech in 2003, he has covered virtually every aspect of the global drug development industry over the past decade. His work includes the popular Fierce 15, which recognizes the most innovative private companies in the business each year. His daily reports keep more than 100,000 subscribers around the world clued in to the latest developments on deals, data and industry trends. Carroll plans to address the biggest influences affecting the fast-changing biopharma industry and what it means to biotech executives in Arizona.
Company Presentation: Invoy Technologies, LLC
Exhaled Breath: A Portal for Pain-Free Biochemical Analysis Invoy is engaged in the development and commercialization of breath analysis devices for a broad range of applications. Invoy plans to offer patients the ability to monitor their health in the convenience of their own home – with a prescription-based breath analysis device called the Voyager. The process is pain-free and the results are quick and accurate; giving patients peace of mind and confidence in using this new-to-the-market device.
Convergence and Personalized Medicine
Greg Yap is Senior Vice President and Lifecycle Leader for Advanced Staining Assays at Ventana Medical Systems. In this role, Greg is responsible for Ventana’s 450 million dollar cancer diagnostic testing business. Ventana’s tests are the market leaders and are used to help guide treatment for over 6 million cancer patients each year worldwide. Previously, Greg was Chief Operating Officer at Cellective Dx, a circulating tumor cell company, and held multiple senior operating roles at Affymetrix.
MSDx: Company Presentation
MSDx, Inc .provides novel biomarker tools for studying disease processes. The company is focused on commercializing both Research Use Only (RUO) and In VitroDiagnostic (IVD) blood test products that will be used in monitoring neurological, autoimmune, and inflammatory disorders.
Keeping People Healthy...at a cost we can afford (Full Presentation)
Michael Birt, director of the Center for Sustainable Health at the Biodesign Institute at Arizona State University. In Birt’s address, “Sustaining Health: How Do We Prevent and Detect Disease Early Enough to Keep People Healthy … at a Cost We Can Afford?” he calls for a shift in our health system to reward cost-effective prevention, early detection and intervention. Such a shift and the technology that it would require has the potential to spur growth among bioscience organizations, reduce patient suffering, and lowering health care costs.